Ocular Therapeutix Annual Revenue, Number of Employees, Growth and Funding
Estimated Revenue & Financials
- Ocular Therapeutix's estimated annual revenue is currently $2M per year.
- Ocular Therapeutix received $37.5M in venture funding in February 2019.
- Ocular Therapeutix's estimated revenue per employee is $9,045
- Ocular Therapeutix's total funding is $187.9M.
- Ocular Therapeutix has 220 Employees.
- Ocular Therapeutix grew their employee count by 48% last year.
- Ocular Therapeutix currently has 8 job openings.
|David Chesbro||Director, QC|
|Robert Davis||Vice President of Market Access|
|Peter Jarrett||Chief Scientific Officer|
|Scott Corning||Senior Vice President, Commercial|
|Veronica Faughnan||Associate Director Clinical Operations|
|Rami Elhayek||Senior Director of Research & Discovery|
|Arthur Driscoll||Vice President Product Development|
|Scott LeBlanc||Director of Finance|
|Dan Bollag||Chief Strategy Officer|
|Naymisha Patel||Vice President, Quality|
What Is Ocular Therapeutix?
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. Ocular Therapeutix's lead product candidate, DEXTENZA (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. The Company's earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, an extended release protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Vita Data Scien...||$7.8M||42||50%||N/A|
|Long Term Pharm...||$10.3M||55||10%||N/A|
Ocular Therapeutix News
In the last twelve months Ocular Therapeutix insiders were buying shares, but not selling. Their average price was about US$3.67.
If you're on the hunt for stocks to watch today, Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a stock to give close attention to. The company ...
Both Ocular Therapeutix Inc. (NASDAQ:OCUL) and Cyclerion Therapeutics Inc. (NASDAQ:CYCN) are Biotechnology companies, competing ...
Ocular Therapeutix Funding
|2017-01-25||$25.0M||Undisclosed||Cantor Fitzgerald & Co||Article|
|2018-01-26||$37.3M||Undisclosed||Piper Jaffray & Co||Article|
Ocular Therapeutix Executive Hires
|2016-01-12||Jonathan H. Talamo||Chief Medical Officer||Article|
|2016-10-21||Andy Hurley||Chief Commercial Officer||Article|
|2017-04-07||George Migausky||Interim Chief Financial Officer||Article|
|2017-08-04||Daniel Bollag||SVP Regulatory Affairs, Pharmacovigilance/Quality||Article|
|2017-09-26||Donald Notman||Chief Financial Officer||Article|
|2018-01-09||Kevin Hanley||SVP Technical Operations||Article|
|2018-12-07||Chad Brines||Vice President, Sales||Article|
Ocular Therapeutix Staff Cuts
|Date||Number of Employees||Location||Reference|